Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 9/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.43 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL672261 | 0.98 | P2RY6 (0.46) | P2RY14P2RY6P2RY2P2RY4B4GALT1 | |
| Cytosine SCHEMBL1687124 | 0.92 | ALDH1A1 (0.44) | P2RY14P2RY6P2RY2P2RY4ALDH1A1 | |
| Cytosine SCHEMBL11403996 | 0.82 | PRKAG1 (0.33) | P2RY6P2RY2P2RY4 | |
| Cytosine SCHEMBL3954369 | 0.79 | P2RY2 (0.50) | P2RY14P2RY6P2RY2P2RY4 | |
| Ribose (Furanose) SCHEMBL8833 | 0.79 | LMNA (0.49) | ALDH1A1 | |
| Ribose (Furanose) SCHEMBL3341287 | 0.79 | LMNA (0.49) | ALDH1A1 | |
| Ribose (Furanose) SCHEMBL2325834 | 0.79 | LMNA (0.49) | ALDH1A1 | |
| Ribose (Furanose) SCHEMBL142622 | 0.79 | LMNA (0.49) | ALDH1A1 | |
| SCHEMBL29656742 | 0.78 | P2RY14 (0.47) | P2RY14P2RY6P2RY2P2RY4B4GALT1 | |
| SCHEMBL3360274 | 0.78 | P2RY14 (0.47) | P2RY14P2RY6P2RY2P2RY4B4GALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5043164-A | Unsaturated phosphatidylethanolamine, micelle forming amphiphile | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1991-08-27 | — | — | US | claimed |
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-10881745-B2 | Formulation of nanostructured gels for increased agent loading and adhesion | Alivio Therapeutics, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3621594-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10300023-B1 | Stabilized assembled nanostructures for delivery of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3452014-A1 | SELF-ASSEMBLED GEL FOR CONTROLLED DELIVERY OF THERMOLABILE AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2018208822-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180318442-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. | 2018-11-08 | — | — | US | disclosed |
| US-9962339-B2 | Stabilized assembled nanostructures for delivery of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170319500-A1 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND LABILE AGENTS | UNITED STATES GOVERNMENT | 2017-11-09 | — | — | US | disclosed |
| WO-2017193138-A1 | SELF-ASSEMBLED GEL FOR CONTROLLED DELIVERY OF THERMOLABILE AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170100342-A1 | STABILIZED ASSEMBLED NANOSTRUCTURES FOR DELIVERY OF ENCAPSULATED AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-13 | — | — | US | disclosed |
| WO-2017062818-A1 | STABILIZED ASSEMBLED NANOSTRUCTURES FOR DELIVERY OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-5043164-A | Unsaturated phosphatidylethanolamine, micelle forming amphiphile | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1991-08-27 | — | — | US | disclosed |
| US-5043164-A | Unsaturated phosphatidylethanolamine, micelle forming amphiphile | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318442-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | LTA, TMSB4X, TLN1 | P2RY14 1660/4885P2RY6 604/4885P2RY2 1380/4885 |
| US-10881745-B2 | Formulation of nanostructured gels for increased agent loading and adhesion | LTA, TMSB4X, TLN1 | P2RY14 1660/4885P2RY6 604/4885P2RY2 1380/4885 |
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | LTA, TMSB4X, TLN1 | P2RY14 1660/4885P2RY6 604/4885P2RY2 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.